BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ANG1005: Updated Phase I/II data

Updated data from an open-label, dose-escalation Phase I/II trial in 56 patients showed that 71% of patients receiving >=420 mg/m 2 IV ANG1005 achieved stable disease (SD) or better, including 10 patients who failed prior taxane therapy....

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >